Vanguard Group Reduces Stake in Viking Therapeutics

Biotechnology company's largest shareholder trims holdings by 1.6%

Mar. 2, 2026 at 11:55pm

Got story updates? Submit your updates here. ›

Vanguard Group Inc., the largest institutional investor in Viking Therapeutics, Inc. (NASDAQ:VKTX), reduced its stake in the biotechnology company by 1.6% during the third quarter of 2025. Vanguard now owns approximately 8.85% of Viking Therapeutics' outstanding shares, down from 9.05% previously.

Why it matters

As a major shareholder, Vanguard's trading activity in Viking Therapeutics can signal broader market sentiment and investor confidence in the company's prospects. The reduced stake, while relatively small, may raise questions about the investment firm's outlook on the biotech firm's future performance.

The details

According to Viking Therapeutics' latest 13F filing, Vanguard Group sold 163,525 shares of the company's stock during the third quarter of 2025. This reduced Vanguard's total holdings to 9,999,107 shares, worth an estimated $262.8 million at the end of the reporting period. Viking Therapeutics' share price has fluctuated between $18.92 and $43.15 over the past 52 weeks.

  • Vanguard Group reduced its stake in Viking Therapeutics during the third quarter of 2025.

The players

Vanguard Group Inc.

A major institutional investor and the largest shareholder of Viking Therapeutics, with an 8.85% stake in the company.

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

Got photos? Submit your photos here. ›

The takeaway

Vanguard's reduced stake in Viking Therapeutics, while relatively small, may signal some uncertainty about the biotech firm's future prospects among major institutional investors. However, Viking Therapeutics remains well-funded and continues to advance its pipeline of promising drug candidates.